Bruno Speder
Bruno Speder is Vice President, Regulatory Affairs at Poolbeg Pharma plc.
JournalArtificial intelligence in drug discovery
The recent publication of papers by the European Medicines Agency (EMA)[1] and the Food and Drug Administration (FDA)[2][3] has spurred the debate on the use of artificial intelligence (AI) in drug development and how it can be used to bring novel compounds to the market.
JournalAccelerated regulatory pathways: Vaccines for tropical diseases
Reproduced from an online seminar presentation, made in collaboration with TOPRA and hVIVO, given on 21 June 2022 by Bruno Speder from hVIVO.